Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrier

dc.contributor.authorLoeck, Maximilian
dc.contributor.authorPlacci, Marina
dc.contributor.authorMuro, Silvia
dc.date.accessioned2023-06-26T09:57:27Z
dc.date.available2024-06-21T05:10:13Z
dc.date.issued2023-06-21
dc.date.updated2023-06-23T10:45:26Z
dc.description.abstractASM deficiency in Niemann-Pick disease type A results in aberrant cellular accumulation of sphingomyelin, neuroinflammation, neurodegeneration, and early death. There is no available treatment because enzyme replacement therapy cannot surmount the blood-brain barrier (BBB). Nanocarriers (NCs) targeted across the BBB via transcytosis might help; yet, whether ASM deficiency alters transcytosis remains poorly characterized. We investigated this using model NCs targeted to intracellular adhesion molecule-1 (ICAM-1), transferrin receptor (TfR), or plasmalemma vesicle-associated protein-1 (PV1) in ASM-normal vs. ASM-deficient BBB models. Disease differentially changed the expression of all three targets, with ICAM-1 becoming the highest. Apical binding and uptake of anti-TfR NCs and anti-PV1 NCs were unaffected by disease, while anti-ICAM-1 NCs had increased apical binding and decreased uptake rate, resulting in unchanged intracellular NCs. Additionally, anti-ICAM-1 NCs underwent basolateral reuptake after transcytosis, whose rate was decreased by disease, as for apical uptake. Consequently, disease increased the effective transcytosis rate for anti-ICAM-1 NCs. Increased transcytosis was also observed for anti-PV1 NCs, while anti-TfR NCs remained unaffected. A fraction of each formulation trafficked to endothelial lysosomes. This was decreased in disease for anti-ICAM-1 NCs and anti-PV1 NCs, agreeing with opposite transcytosis changes, while it increased for anti-TfR NCs. Overall, these variations in receptor expression and NC transport resulted in anti-ICAM-1 NCs displaying the highest absolute transcytosis in the disease condition. Furthermore, these results revealed that ASM deficiency can differently alter these processes depending on the particular target, for which this type of study is key to guide the design of therapeutic NCs.© 2023. Controlled Release Society.ca
dc.format.extent39 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina6597178
dc.identifier.issn2190-3948
dc.identifier.pmid37341882
dc.identifier.urihttps://hdl.handle.net/2445/199862
dc.language.isoengca
dc.publisherSpringer Natureca
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1007/s13346-023-01374-z
dc.relation.ispartofDrug Delivery And Translational Research, 2023
dc.relation.urihttps://doi.org/10.1007/s13346-023-01374-z
dc.rights(c) Controlled Release Society, 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
dc.subject.classificationMalalties de Niemann-Pick
dc.subject.classificationSistemes d'alliberament de medicaments
dc.subject.otherNiemann-Pick diseases
dc.subject.otherDrug delivery systems
dc.titleEffect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrierca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
2023_DDTR_Effect_LoeckM_postprint.pdf
Mida:
1.48 MB
Format:
Adobe Portable Document Format